Nature Communications (Jan 2023)
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer
- Takuya Tsujino,
- Tomoaki Takai,
- Kunihiko Hinohara,
- Fu Gui,
- Takeshi Tsutsumi,
- Xiao Bai,
- Chenkui Miao,
- Chao Feng,
- Bin Gui,
- Zsofia Sztupinszki,
- Antoine Simoneau,
- Ning Xie,
- Ladan Fazli,
- Xuesen Dong,
- Haruhito Azuma,
- Atish D. Choudhury,
- Kent W. Mouw,
- Zoltan Szallasi,
- Lee Zou,
- Adam S. Kibel,
- Li Jia
Affiliations
- Takuya Tsujino
- Division of Urology, Department of Surgery, Brigham and Women’s Hospital & Harvard Medical School
- Tomoaki Takai
- Division of Urology, Department of Surgery, Brigham and Women’s Hospital & Harvard Medical School
- Kunihiko Hinohara
- Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School
- Fu Gui
- Division of Urology, Department of Surgery, Brigham and Women’s Hospital & Harvard Medical School
- Takeshi Tsutsumi
- Division of Urology, Department of Surgery, Brigham and Women’s Hospital & Harvard Medical School
- Xiao Bai
- Division of Urology, Department of Surgery, Brigham and Women’s Hospital & Harvard Medical School
- Chenkui Miao
- Division of Urology, Department of Surgery, Brigham and Women’s Hospital & Harvard Medical School
- Chao Feng
- Division of Urology, Department of Surgery, Brigham and Women’s Hospital & Harvard Medical School
- Bin Gui
- Division of Urology, Department of Surgery, Brigham and Women’s Hospital & Harvard Medical School
- Zsofia Sztupinszki
- Computational Health Informatics Program, Boston Children’s Hospital
- Antoine Simoneau
- Department of Pathology, Massachusetts General Hospital & Harvard Medical School
- Ning Xie
- Vancouver Prostate Centre, Vancouver General Hospital
- Ladan Fazli
- Vancouver Prostate Centre, Vancouver General Hospital
- Xuesen Dong
- Vancouver Prostate Centre, Vancouver General Hospital
- Haruhito Azuma
- Department of Urology, Osaka Medical and Pharmaceutical University
- Atish D. Choudhury
- Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School
- Kent W. Mouw
- Department of Radiation Oncology, Dana-Farber Cancer Institute & Brigham and Women’s Hospital & Harvard Medical School
- Zoltan Szallasi
- Computational Health Informatics Program, Boston Children’s Hospital
- Lee Zou
- Department of Pathology, Massachusetts General Hospital & Harvard Medical School
- Adam S. Kibel
- Division of Urology, Department of Surgery, Brigham and Women’s Hospital & Harvard Medical School
- Li Jia
- Division of Urology, Department of Surgery, Brigham and Women’s Hospital & Harvard Medical School
- DOI
- https://doi.org/10.1038/s41467-023-35880-y
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 19
Abstract
Identifying prostate cancer patients who may respond well to PARP inhibitors is important for their success in the clinic. Here, using a genome-wide CRISPR-Cas9 knockout screen, the authors identify MMS22L as a biomarker for sensitivity to PARP inhibition in BRCA1/2-proficient prostate cancer.
